Amgen and tscan therapeutics announce collaboration to identify novel targets in crohn's disease

Collaboration brings together tscan's proprietary target discovery platform and amgen's inflammation therapeutic expertise and research capabilities tscan to receive $30 million upfront with potential development and commercial milestone payments of over $500 million thousand oaks, calif. and waltham, mass.
TCRX Ratings Summary
TCRX Quant Ranking